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Intact cNOS-NO-cGMP Pathway in the Failing Human
Heart
We previously have shown that the angiotensin II receptor. type 1a (ATlaR)
message transiently decreases during ang II stimulation of cultured rat aor-
tic vascular smooth muscle cells (VSMC); and, it has been previously re-
ported by others that the mechanism of this decrease in cultured kidney
cells is through cAM P dependent pathways. In this study we examined the
signal transduction pathway of this regUlation in quiescent VSMC. Total cel-
lular RNA was harvested after time course exposure to reagents, Northern
blotted and probed. AT1aR message abundance decreased beginning two
hours after exposure to ang II (10 nM) and reached a minimum at 4 hours
after stimulation of 25% of baseline level. The protein kinase C (PKC) stimula-
tor, PMA (50 nM), caused a decrease in ATlaR message level with the same
time course and to the same extent as ang II. Downregulation of PKC with 24
hour prior exposure to PDBU (500 nM) blocked the decrease in AT1aR mes-
sage caused by PMA. However, pretreatment with either PDBU orthe potent
PKC inhibitor calphostin C (50 nM) did not block the decrease of AT1aR mes-
sage level caused by ang II. In contrast. stimulation of cAMP with forskolin
(50 mM). cholera toxin (1 ang/ml) or the soluble analog 8-bromocyclic AM P(1
CMEC and in ARVM in a dose dependent manner that was maximal 4-8
hours after treatment. This effect of All was abolished after coincubation
with the angiotensin II receptor antagonist (AT-1) losartan (10-6 M), and the
ET-1 response was inhibited by the peptide endothelin type A (ETA) antago-
nist BO-123 (10-6 M). To determine whether bFGF itself autoregulates bFGF
mRNA abundance, ARVM and CMEC were treated with rh bFGF (20ng/mll. A
ninefold increase in bFGF mRNA was detected, thus indicating positive au-
toregulation. A marked induction of atrial natriuretic peptide mRNA, known
as a molecular marker of phenotype dedifferentiation in hypertrophy, was
observed after 24 and 48 hrs incubation with rh bFGF in ARVM. Finally, the
inflammatory cytokine interleukin 113 (rh IL-1f3) upregulates bFGF gene ex-
pression in ARVM, a response that could be amplified by interferon y (rm
IFN-y).
Thus, bFGF gene expression in ARVM and CMEC from rat heart is regu-
lated by All and ET-1 through the AT-1 receptor and (ETA) receptor subtypes.
The upregulation of bFGF gene transcription in response to various stimuli
known to affect myocyte and endothelial growth suggest a role for bFGF as a
signalling peptide in the hypertrophic response of adult ventricular myocytes
and cardiac microvascular endothelial cells.
Chi-Ming Wei. John Lust. Zvonimir Katusic. Michihisa Jougasaki, Denise Heublein,
Sharon Sandberg. Debra Lewis, Virginia Miller, Christopher McGregor,
John Burnett. Jr. Mayo Clinic, Rochester, MN
Nitric oxide (NO) is a potent endothelium-derived relaxing factor which also
may modulate cardiac myocyte inotropism and growth via increases in
cGMP. While both the constitutive (cNOS) and inducible (iNOS)forms of nitric
oxide synthase have been detected in mammalian hearts, the overall pres-
ence and activity of the cNOS-NO-cGMP pathway in the normal and failing
human heart remains poorly defined. The present studies were designed to
investigate the cNOS-NO-cGMP pathway in normal and failing human atrial
and ventricular myocardium and to determine plasma NO and cGMP in the
presence and absence of CHE Myocardial tissue and plasma were obtained
from five end-stage heart failure patients undergoing cardiac transplantation
and five cardiac donors. Normal plasma NO and cGMP were also determined
in normal humans without disease. cNOS production and localization were
determined utilizing Northern blot analysis, in situ hybridization and immuno-
histochemistry with probes for endothelial-NOS and brain-NOS. Plasma and
tissue NO were measured by nitrate determination utilizing chemilumines-
cence. Northern blot analysis and in situ demonstrated cNOS to be present
and localized to atrial and ventricular myocytes in equal concentrations and
distributions in normal and failing hearts. Tissue NO as determined by nitrate
concentration was detectable and equal in normal and failing hearts while
plasma NO concentration tended to be increased in CHF patients. Cardiac
tissue cGMP paralleled tissue NO, although, plasma cGMP concentration
was significantly increased in CHF patients compared with normal subjects.
The present studies demonstrate that cNOS mRNA and cNOS protein are
present in the normal human heart and this cNOS-NO-cGMP pathway is pre-
served in the failing human heart. These studies suggest that this paracrine
and autocrine pathway may continue to function in the control of myocardial
function in the failing human myocardium.
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Mechanism of Decrease of Angiotensin II Receptor
Message Through Dual Signal Transduction
Pathways in Vascular Smooth Muscle
Stanley A. Rubin, Tim Bui, Lee Carter VA Medical Center, Long Beach and University
of California, Irvine, CA
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Fibroblast growth factors (FGFs) have been demonstrated to regulate myo-
genic differentiation. Recently, forms of FGF have been generated that reside
in the cytoplasm and appear to be biologically active. suggesting that an in-
tracellular form of FGF may be able to transduce its signal through signaling
pathways independent of its interaction with cell surface (transmembrane)
FGF receptors (FGFR). We report in this study a potential mechanism by
which such signaling can be modulated by an intracellular form of the recep-
tor (I-FGFR). To generate this form of the receptor, the cDNA encoding the 2
IgG-like domain form of the murine transmembrane FGFR was mutated to re-
move its signal sequence and acidic box by PCR mutagenesis. This construct
was then epitope-tagged to allow it to be distinguished from the endogenous
surface FGF receptor. When the I-FGFR was transientlytransfected into COS
cells, a diffuse and reticular pattern was observed by indirect immunofluo-
rescence microscopy, indicating cytoplasmic localization with association to
organized intracellular structures, such as cytoskeleton or organellar mem-
brane. To test for the biologic effect of the I-FGFR, stable cell lines containing
the I-FGFR were generated in Sol 8 cells. Quadruplicate samples of four cell
lines expressing high levels of the I-FGFR, and four control cell lines trans-
fected with vector alone, were grown in mitogen poor medium (5% horse
serum). Their ability to differentiate was assessed by their levels of creatine
kinase activity normalized to total soluble protein (nmol NADPH/min/mg pro-
tein):
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Constitutive Expression of an Intracellular Form of
Fibroblast Growth Factor Receptor Triggers
Myogenic Differentiation
The results demonstrate that the intracellular form of the FGF receptor lo-
calizes to the cytoplasm of myocytes, and the increased expression of this
receptor isoform triggers myogenic differentiation. We propose that this re-
ceptor promotes differentiation by binding endogenous FGF, and thus inhibit-
ing the activity of FGF that normally preserves the undifferentiated state. The
ability to generate and express the intracellular FGF receptor, therefore, may
be a generally useful method of modulating FGF dependent regulation of
proliferation and differentiation of other cell types such as smooth muscle
and transformed cells.
The down-regulation of 131 AR and AT1 receptors was significantly related
(r = 0.62, n = 12, P < 0.05)
Conclusions: (1) Compared to 13 adrenergic receptors ang II receptors are
very low density in the human heart. (2) The AT1 receptor sUbtype predomi-
nates in the nonfailing human heart. (3) ATl but not AT2 receptors are down-
regulated in failing heart. (4) Down-regulation of Ang-II AT1 receptor is similar
in degree to down-regulation of 131-adrenergic receptors. These data suggest
that the AT1 and 131 receptors are respectively exposed to increased concen-
trations of mutually activatedlinduced norepinephrine and Ang-II in the failing
human heart.
Basic fibroblast growth factor (bFGF) has been shown to stimulate protein
synthesis in adult rat ventricular myocytes (ARVM) and DNA synthesis in mi-
crovascular endothelial cells (CM EC). To determine whether Angiotensin 11
(All) and Endothelin I (ET-1), known as peptides affecting myocyte growth,
regulate bFGF gene expression in the myocardium we examined the effects
of these two peptide autacoids on bFGF mRNA abundance in both cardiac
cell types. Baseline levels for bFGF mRNA in freshly isolated ARVM were
4 to 5 fold lower than in CMEC in RNase protection assays. All (10-6 -
10-8 M) and ET-1 (10-8 - 10-10 M) increased bFGF mRNA abundance in
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Regulation of Basic Fibroblast Growth Factor Gene
Expression in Rat Cardiac Microvascular Endothelial
Cells and Adult Ventricular Myocytes
Thomas A. Fischer. Krishna Singh, Alborz Alali, Min-Ae Lee, David Kaye. Albert
p. Gatbut. Jean Luc Balligand, Ralph A. Kelly, Thomas W. Smith Cardiovascular
Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical
School, Boston, MA
